Amate Medical, a Rising Star in China's Pan-Vascular Intervention Sector, Secures Over RMB 200 Million in Series D Funding with Post-Money Valuation Exceeding RMB 1.5 Billion
AMT Medical Inc.
3D-Printed Vascular Stent Technology Developer
Recently, another major positive development has emerged in the domestically produced high-end implantable and interventional device sector:Beijing AMT Medical Inc. Completes Over RMB 200 Million Series D Funding, Post-Money Valuation Exceeds RMB 1.5 Billion, led by the Zhe Sheng Xietong Life & Health Fund, with co-investments from institutions including the Henan Key Intellectual Property Fund and the Global Hedge Fund.
It is worth noting that, in addition to successful financing, thisHolds China's first Class III registration certificate for a CO2 contrast injection product and is the world's only developer of fully bioresorbable stents for both coronary and peripheral applications.The company that has entered clinical trials filed its listing application with the Hong Kong Stock Exchange last year and obtained the CSRC filing for overseas listing,Expected to officially list on the Hong Kong Stock Exchange in the second half of this year., poised to become "the first domestic pan-vascular interventional stock".
Why AMT?
Hardcore Technology Is the True Foundation for Securing Capital Backing
Under centralized procurement, profits for traditional medical consumables have been compressed to the freezing point. However, genuinely innovative products that feature proprietary technologies and address unmet clinical needs have secured a firm foothold in the fiercely competitive market, driven by their scarcity and rigid demand. AMT Medical stands out as the most representative high-potential investment target.
For a long time, the global bioresorbable scaffold market has been firmly monopolized by industry giants such as Abbott and Boston Scientific through laser cutting technology, making it extremely difficult for Chinese manufacturers to break through. However, AMT has forged a fully proprietary and differentiated path:
Proprietary 3D-MAP Multi-Axis Precision Printing Technology:Revolutionizing traditional subtractive manufacturing, it enables zero-waste, one-step forming that increases material utilization by several times, and facilitates the fabrication of complex stent structures unattainable by conventional processes,Comprehensively leading in wall apposition, radial strength, and endothelialization rate, while completely circumventing core overseas patents.
Self-Developed PLCL Medical-Grade Biodegradable Material:Led the national "Jiebang Guashuai" (Open Competition) project,Achieves a molecular-level balance between rigidity and flexibility, with non-toxic degradation products and a well-defined metabolic pathway., eliminating dependence on imported materials at the source
AMT's product portfolio, each directly addressing critical unmet clinical needs:
Xingluoyu® Carbon Dioxide Angiography System:Officially approved by the NMPA in April 2026, isChina's first approved Class III injectable CO₂ contrast agent, non-nephrotoxic and free from iodine allergy risk， perfectly addressing the contrast-enhanced imaging challenges for high-risk patients with renal insufficiency, allergy to iodinated contrast agents, hyperthyroidism, and other conditions, it has already been marketed in over 20 countries overseas and, following approval in China, is poised to usher in its inaugural year of mass commercialization.
Bioresorbable Stent Pipeline:The World's Only to Simultaneously Develop Fully Biodegradable Coronary and Peripheral StentsThe company entering clinical trials has demonstrated zero thrombosis in coronary stents at the 6-year follow-up, with long-term safety reaching internationally leading standards. Both products have entered the National Special Approval Pathway for Innovative Medical Devices.
Survival Rules Amid Industry Consolidation
Choosing the right innovation track is more important than working hard blindly!!
It is worth noting that, like all R&D-focused medical device companies, AMT Medical's commercialization is still in the ramp-up phase, and achieving profitability in the short term may prove challenging; however, this successful financing round precisely underscores that:Focusing on innovative tracks that address unmet clinical needs and feature proprietary barriers is the current trend in the development of China's medical device industry.
However, we are fully aware that the vast majority of our distributor partners are currently stuck at a highly challenging crossroads:
✅ Centralized procurement has slashed profits on traditional medical consumables to rock bottom, resulting in higher sales volumes but lower margins, with companies even operating at a loss merely to maintain market presence.
✅ Seeking to pivot into innovative sectors but hindered by information asymmetry, unable to distinguish genuine blue-ocean opportunities from pseudo-concepts.
✅ Unable to assess the technical barriers of the products, leaving it unclear which will sustain long-term profitability and which are merely short-lived trends.
✅ By the time you hear about this sector, others have already reaped substantial profits; entering the market then leaves you with only marginal returns or exposes you to costly pitfalls.
In the hundred-million-yuan market tracks for many innovative medical devices, numerous distributors have not even tracked product launch news, let alone made advance strategic preparations. Meanwhile, those who secured the information earlier and selected the right products are already enjoying the high-margin dividends driven by technological barriers.
Break Down Information Barriers!
This White Paper Helps You Identify the Next Breakout Product
To assist medical device distributors nationwideBridge the Industry Information Gap: Precisely Target High-Profit Tracks in Innovative Medical Devices, to fully seize the core opportunities driving industry development, we proudly present and launch《Breaking Boundaries · Leading the Way: A White Paper on China's Medical Device Innovation from a Global Perspective》.
This book not onlyProvides a comprehensive overview of nearly 400 innovative products globally and in China, along with an in-depth analysis of 72+ benchmark product cases across 16 major medical device segments., is an innovative roadmap specifically tailored for medical device distributors/agents/enterprises.
Industry's First White Paper on Innovative Medical Devices
Original Price: ¥499
Customer Appreciation Special Promotion
Only 269 RMB!!!
?Click the image for details?
*Advertisement
White PaperFocusing on cardiovascular intervention, surgical robotics, medical imaging, tumor ablation, orthopedics, endoscopes, novel medical materials, etc.# 16 High-Growth Trending Sectors，carefully selected innovative products, with detailed coverage from specific aspects to comprehensive overviewsDetail the current market landscape, technological trends, and competitive environment, enabling distributors to accurately gauge market dynamics.
Taking the currently most popular surgical robots as an example, the white paper not only introduces the mainstream products currently on the market, but alsoConducted an in-depth analysis of the technical features, clinical application efficacy, and market strategies of various brands.. Through comparative analysis, distributors can clearly identify the advantages and disadvantages of different products, thereby enabling them to make more informed decisions.
Innovative WhiteBrochure Inner Pages Display
In "pseudo-innovation”In a market saturated with proliferating products, the white paper's comprehensive product landscape assessment feature proves particularly crucial.
It not only lists 75 global and 315 domestic innovative medical device products, but also fromPolicy Support, Market Prospects, Core Technologies, Clinical Applications, Competitive Landscape, Manufacturer Strengthcomprehensively evaluated across multiple dimensions. By breaking down information barriers and reducing information asymmetry, it helps medical device distributors gain an in-depth and comprehensive understanding of the innovative medical device products currently available on the market.
For example, in the field of cardiovascular intervention,, the white paper provides a detailed comparison of coronary stent products from different brands, including their materials, design, clinical efficacy, pricing, and manufacturers' production line information, offering distributors an objective and comprehensive reference.。
The Industry's First White Paper on Innovative Medical Devices
Original Price: ¥499
Customer Appreciation Special Promotion
Only 269 RMB!!!
?Click the image for details?
White Paper Table of Contents Preview
Anchoring the Development Course for the Next Decade, Seizing the Strategic Market High Ground
The white paper not only conducts a market analysis grounded in current realities, but also adopts a global perspective,From multiple dimensions including industrial development, clinical applications, multidisciplinary integration, the rise of domestic products, and cutting-edge research, providing an in-depth analysis of the five major development trends for innovative medical devices over the next decade, such asApplication Prospects of Emerging Technologies such as Artificial Intelligence, Big Data, and 3D Printing in the Medical Device Industry, and the Impact of Social Factors including Population Aging and the Rising Prevalence of Chronic Diseases on Market Demand.
Meanwhile, the white paper also provides an in-depth analysis of six prominent niche sectors, offering detailed insights into AI healthcare, minimally invasive interventions, regenerative medicine, digital therapeutics, smart rehabilitation, and medical robotics. It identifies sub-sector opportunities for distributors, enabling them to address immediate market demands while strategically planning for long-term growth.
Overview of China's Support Policies: Accurately Capturing Industry Trends
Support policies for innovative medical devices, from the perspective of top-level design, represent the state's supportive stance toward the development of innovative medical devices,This has also affected the level of support for innovative medical technologies, from the National Health Commission and the National Healthcare Security Administration at the top down to hospitals at all levels.。From an implementation perspective, DRG exemption payments for innovative medical devices, green channels for hospital market access, and similar measures impact their entry into hospitals.
Innovation White PaperConducted an in-depth analysis of national and provincial support policies for innovative medical devices across China over the past three years,Comprehensively covering everything from top-level design and financial support to market access,Help medical device distributors gain early insights into policy trends.
A comprehensive grasp of national and provincial support policies for innovative medical devices unlocks the strategic compass for industry development and the master key to hospital market access and product promotion.
In this innovation-driven new era, only those distributors who can accurately grasp policy directions, keenly identify market trends, and precisely select products will be able to maintain an unassailable position in the face of intense competition.
Innovation is no longer a mere embellishment, but an essential requirement and a critical survival skill for distributors.Let us take 《Breaking Boundaries · Leading the Way》 as our guideSouth, setting sail on the tide of innovation, seizing the first-mover advantage, and ushering in a new era of medical device distribution!
The Industry's First White Paper on Innovative Medical Devices
Original Price: ¥499
Customer Appreciation Special Promotion
Only ¥269!!!
?Click image for details?
*Advertisement